Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Clinical Studies

Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas

Abstract

Background

Pazopanib is active in refractory soft-tissue sarcoma (STS) and significantly prolongs PFS. Prior studies of combinations of metronomic topotecan with pazopanib have indicated preclinical evidence of response in patients with sarcoma.

Methods

This prospective, single arm, phase II study evaluated the efficacy of the combination of pazopanib with topotecan in patients with metastatic or unresectable non-adipocytic STS. Furthermore, it incorporated exploratory arms for osteosarcoma and liposarcoma. The primary endpoint was progression-free rate at 12 weeks in the non-adipocytic STS cohort.

Results

57.5% of patients in the non-adipocytic STS cohort were progression free at 12 weeks, which did not meet the primary endpoint of the study (66%). The exploratory osteosarcoma cohort exceeded previously established phase II trial comparator data benchmark of 12% with a PFR at 12 weeks of 69.55%. Treatment with the combination of pazopanib and topotecan was accompanied by a grade 3 or 4 toxicities in most patients.

Conclusions

In this prospective trial in refractory metastatic or unresectable STS and osteosarcoma, the combination of pazopanib with topotecan did not meet its primary endpoint of progression-free rate at 12 weeks. The combination of pazopanib with topotecan was associated with a high degree of toxicity.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Progression-free survival for cohorts 1 (non-adipocytic soft-tissue sarcoma), 2 (osteosarcoma) and 3 (liposarcoma).
Fig. 2: Overall survival of cohort 1 (soft-tissue sarcoma), cohort 2 (osteosarcoma) and cohort 3 (liposarcoma).

References

  1. 1.

    Clark, M. A., Fisher, C., Judson, I. & Meirion Thomas, J. Soft-tissue sarcomas in adults. N. Engl. J. Med. 353, 701–711 (2005).

    CAS  Article  Google Scholar 

  2. 2.

    Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020).

    Article  Google Scholar 

  3. 3.

    Benjamin, R. S. & George, S. Soft Tissue Sarcoma Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 16, 536–563 (2018).

  4. 4.

    Judson, I., Verweij, J., Gelderblom, H., Hartmann, J. T., Schöffski, P., Blay, J. Y. et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 15, 415–423 (2014).

    CAS  Article  Google Scholar 

  5. 5.

    Van Glabbeke, M., van Oosterom, A. T., Oosterhuis, J. W., Mouridsen, H., Crowther, D., Somers, R. et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens–a European Organization for Research and Treatment of Cancer Soft Tissue and Bone. J. Clin. Oncol. 17, 150–157 (1999).

    Article  Google Scholar 

  6. 6.

    Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y. et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364, 1127–1134 (2004).

    CAS  Article  Google Scholar 

  7. 7.

    Demetri, G. D., Von Mehren, M., Jones, R. L., Hensley, M. L., Schuetze, S. M., Staddon, A. et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J. Clin. Oncol. 34, 786–793 (2016).

    CAS  Article  Google Scholar 

  8. 8.

    Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, asonc02906q0015 (2002).

    Article  Google Scholar 

  9. 9.

    Ferrara, N., Gerber, H.-P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669–676 (2003).

    CAS  Article  Google Scholar 

  10. 10.

    Van Der Graaf, W. T. A., Blay, J. Y., Chawla, S. P., Kim, D. W., Bui-Nguyen, B., Casali, P. G. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379, 1879–1886 (2012).

    Article  Google Scholar 

  11. 11.

    Grünwald, V., Karch, A., Schuler, M., Schöffski, P., Kopp, H.-G., Bauer, S. et al. Randomized comparison of pazopanib and doxorubicin as first-line treatment in patients with metastatic soft tissue sarcoma age 60 years or older: results of a German Intergroup Study. J. Clin. Oncol. 38, 3555–3564 (2020).

    Article  Google Scholar 

  12. 12.

    Schmoll, H.-J., Lindner, L. H., Reichardt, P., Heißner, K., Kopp, H.-G., Kessler, T. et al. Efficacy of pazopanib with or without gemcitabine in patients with anthracycline- and/or ifosfamide-refractory soft tissue sarcoma. JAMA Oncol. 7, 255 (2021).

    Article  Google Scholar 

  13. 13.

    Miller, D. S., Blessing, J. A., Kilgore, L. C., Mannel, R. & Van Le, L. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas. Am. J. Clin. Oncol. 23, 355–357 (2000).

    CAS  Article  Google Scholar 

  14. 14.

    Reichardt, P., Oechsle, K., Pink, D., Bokemeyer, C., Schneller, F., Issels, R. et al. An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest. New Drugs 21, 481–486 (2003).

  15. 15.

    Saylors, R. L., Stine, K. C., Sullivan, J., Kepner, J. L., Wall, D. A., Bernstein, M. L. et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group Phase II Study. J. Clin. Oncol. 19, 3463–3469 (2001).

    CAS  Article  Google Scholar 

  16. 16.

    Kumar, S., Mokhtari, R. B., Sheikh, R., Wu, B., Zhang, L., Xu, P. et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin. Cancer Res. 17, 5656–5667 (2011).

    CAS  Article  Google Scholar 

  17. 17.

    Hashimoto, K., Man, S., Xu, P., Cruz-Munoz, W., Tang, T., Kumar, R. et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol. Cancer Ther. 9, 996–1006 (2010).

    CAS  Article  Google Scholar 

  18. 18.

    Kerklaan, B. M., Lolkema, M. P. J., Devriese, L. A., Voest, E. E., Nol-Boekel, A., Mergui-Roelvink, M. et al. Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours. Br. J. Cancer 113, 706–715 (2015).

    CAS  Article  Google Scholar 

  19. 19.

    Schöffski, P., Chawla, S., Maki, R. G., Italiano, A., Gelderblom, H., Choy, E. et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387, 1629–1637 (2016).

    Article  Google Scholar 

  20. 20.

    Lagmay, J. P., Krailo, M. D., Dang, H., Kim, A., Hawkins, D. S., Beaty, O. et al. Outcome of patients with recurrent osteosarcoma enrolled in seven Phase II trials through children’s cancer group, Pediatric Oncology Group, and Children’s Oncology Group: Learning From the Past to Move Forward. J. Clin. Oncol. 34, 3031–3038 (2016).

    Article  Google Scholar 

  21. 21.

    Duffaud, F., Mir, O., Boudou-Rouquette, P., Piperno-Neumann, S., Penel, N., Bompas, E. et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 20, 120–133 (2019).

    CAS  Article  Google Scholar 

  22. 22.

    Italiano, A., Mir, O., Mathoulin-Pelissier, S., Penel, N., Piperno-Neumann, S., Bompas, E. et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 21, 446–455 (2020).

    CAS  Article  Google Scholar 

  23. 23.

    Smeland, S., Bielack, S. S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M. D. et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur. J. Cancer 109, 36–50 (2019).

    Article  Google Scholar 

  24. 24.

    Mirabello, L., Troisi, R. J. & Savage, S. A. Osteosarcoma incidence and survival rates from 1973 to 2004. Cancer 115, 1531–1543 (2009).

    Article  Google Scholar 

  25. 25.

    Gaspar, N., Sirvent, F. J. B., Venkatramani, R., Longhi, A., Lervat, C., Casanova, M. et al. Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory (r/r) osteosarcoma. Ann. Oncol. 30, v688 (2019).

    Article  Google Scholar 

Download references

Acknowledgements

We are indebted to all the patients, and co-investigators who have participated in this trial. We want to thank the following collaborators of their assistance in preparation, and funding of this project.

Author information

Affiliations

Authors

Contributions

Manuscript preparation: B.S., M.A. Study design: N.M., M.A. Patient data and study materials: M.M., S.A., S.R., V.M., A.H., P.O., J.C., S.A., R.C., S.O., B.V.T., M.A. Data analysis and interpretation: B.S., M.A., I.H. Manuscript editing and review: All.

Corresponding author

Correspondence to Mark Agulnik.

Ethics declarations

Ethics approval and consent to participate

This study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board of each participating institution—Northwestern University, University of Iowa, Mayo Clinic, Medical College of Wisconsin and Washington University School of Medicine. Furthermore, written consent was obtained from all participants.

Consent to publish

Not applicable.

Data availability

All data are available upon request.

Competing interests

The authors declare no competing interests.

Funding information

Research was sponsored by Northwestern University, with limited collaborative support from Novartis Pharmaceuticals.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schulte, B., Mohindra, N., Milhem, M. et al. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. Br J Cancer (2021). https://doi.org/10.1038/s41416-021-01448-0

Download citation

Search

Quick links